4ign

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 7: Line 7:
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4ign FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4ign OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4ign RCSB], [http://www.ebi.ac.uk/pdbsum/4ign PDBsum]</span></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4ign FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4ign OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4ign RCSB], [http://www.ebi.ac.uk/pdbsum/4ign PDBsum]</span></td></tr>
</table>
</table>
 +
== Function ==
 +
[[http://www.uniprot.org/uniprot/ACMSD_HUMAN ACMSD_HUMAN]] Converts alpha-amino-beta-carboxymuconate-epsilon-semialdehyde (ACMS) to alpha-aminomuconate semialdehyde (AMS). ACMS can be converted non-enzymatically to quinolate (QA), a key precursor of NAD, and a potent endogenous excitotoxin of neuronal cells which is implicated in the pathogenesis of various neurodegenerative disorders. In the presence of ACMSD, ACMS is converted to AMS, a benign catabolite. ACMSD ultimately controls the metabolic fate of tryptophan catabolism along the kynurenine pathway.<ref>PMID:19843166</ref> <ref>PMID:12140278</ref>
<div style="background-color:#fffaf0;">
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
== Publication Abstract from PubMed ==

Revision as of 13:52, 24 December 2014

2.32 Angstrom X-ray Crystal structure of R47A mutant of human ACMSD

4ign, resolution 2.33Å

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools